Abstract
Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.
Keywords:
AD; Alzheimer’s disease; Gamma-secretase; LY450139; neurodegeneration; semagacestat.
MeSH terms
-
Alanine / adverse effects
-
Alanine / analogs & derivatives*
-
Alanine / chemistry
-
Alanine / pharmacology
-
Alanine / therapeutic use
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / metabolism
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / physiology
-
Amyloid beta-Peptides / blood
-
Amyloid beta-Peptides / cerebrospinal fluid
-
Amyloid beta-Protein Precursor / metabolism
-
Azepines* / adverse effects
-
Azepines* / chemistry
-
Azepines* / pharmacology
-
Azepines* / therapeutic use
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Molecular Structure
-
Multicenter Studies as Topic
-
Neuroprotective Agents* / adverse effects
-
Neuroprotective Agents* / chemistry
-
Neuroprotective Agents* / pharmacology
-
Neuroprotective Agents* / therapeutic use
-
Peptide Fragments / blood
-
Peptide Fragments / cerebrospinal fluid
-
Protein Processing, Post-Translational
-
Receptors, Notch / antagonists & inhibitors
-
Receptors, Notch / physiology
-
Signal Transduction / drug effects
Substances
-
Amyloid beta-Peptides
-
Amyloid beta-Protein Precursor
-
Azepines
-
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
-
Neuroprotective Agents
-
Peptide Fragments
-
Receptors, Notch
-
amyloid beta-protein (1-40)
-
Amyloid Precursor Protein Secretases
-
Alanine